Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0924 ECP XWPharma
BioCentury & Getty Images

Emerging Company Profile

XWPharma: timing therapy to biological rhythm

XWPharma to use $40M series C to advance two lead neurology programs

XWPharma develops CNS therapies with validated targets using novel formulations to synchronize with the body’s natural rhythm.

Sep 25, 2020 | 11:20 PM GMT

Wuhan-based XWPharma is developing novel formulations of existing neurology drugs designed to synchronize

Read the full 609 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers